Пятый элемент здоровья. Как использовать менструальный цикл для поддержания жизненно важных функций организма - Лиза Хендриксон-Джек
Шрифт:
Интервал:
Закладка:
44. Teegarden, Dorothy, and Shawn S. Donkin. “Vitamin D: emerging new roles in insulin sensitivity.” Nutrition Research Reviews 22, no. 1 (2009): 82–92; Kotsa, Kalliopi, Maria P. Yavropoulou, Olympia Anastasiou, and John G. Yovos. “Role of vitamin D treatment in glucose metabolism in polycystic ovary syndrome.” Fertility and Sterility 92, no. 3 (2009): 1053–1058.
45. Pal, Lubna, Heping Zhang, Joanne Williams, Nanette F. Santoro, Michael P. Diamond, William D. Schlaff, Christos Coutifaris et al. “Vitamin D status relates to reproductive outcome in women with polycystic ovary syndrome: secondary analysis of a multicenter randomized controlled trial.” The Journal of Clinical Endocrinology & Metabolism 101, no. 8 (2016): 3027–3035.
46. Muneyyirci-Delale, O., V.L. Nacharaju, M. Dalloul, S. Jalou, M. Rahman, B.M. Altura, and B.T. Altura. “Divalent cations in women with PCOS: implications for cardiovascular disease.” Gynecological Endocrinology 15, no. 3 (2001): 198–201; von Ehrlich, B., M. Barbagallo, H.G. Classen, F. Guerrero-Romero, F.C. Mooren, M. Rodriguez-Moran, W. Vierling, J. Vormann, and K. Kisters. “Significance of magnesium in insulin resistance, metabolic syndrome, and diabetes recommendations of the Association of Magnesium Research e.V.” Trace Elements and Electrolytes 34, no. 3 (2017): 124–129; Barbagallo, Mario, and Ligia J. Dominguez. “Magnesium and type 2 diabetes.” World Journal of Diabetes 6, no. 10 (2015): 1152–1157; Dibaba, Daniel T., Pengcheng Xun, and Ka He. “Dietary magnesium intake is inversely associated with serum C-reactive protein levels: meta-analysis and systematic review.” European Journal of Clinical Nutrition 68, no. 4 (2014): 510–516.
47. Guerrero-Romero, F., H.E. Tamez-Perez, G. González-González, A.M. Salinas-Martinez, J. Montes-Villarreal, J.H. Trevino-Ortiz, and M. Rodriguez-Moran. “Oral magnesium supplementation improves insulin sensitivity in non-diabetic subjects with insulin resistance. a double-blind placebo-controlled randomized trial.” Diabetes and Metabolism 30, no. 3 (2004): 253–258; Simental-Mendía, Luis E., Martha Rodríguez-Morán, and Fernando Guerrero-Romero. “Oral magnesium supplementation decreases C-reactive protein levels in subjects with prediabetes and hypomagnesemia: a clinical randomized double-blind placebo-controlled trial.” Archives of Medical Research 45, no. 4 (2014): 325–330.
48. Kanafchian, Maryam, Soleiman Mahjoub, Sedigheh Esmaeilzadeh, Maryam Rahsepar, and Abbas Mosapour. “Status of serum selenium and zinc in patients with the polycystic ovary syndrome with and without insulin resistance.” Middle East Fertility Society Journal (2017): 1–5; Guler, Ismail, Ozdemir Himmetoglu, Ahmet Turp, Ahmet Erdem, Mehmet Erdem, M. Anıl Onan, Cagatay Taskiran, Mine Yavuz Taslipinar, and Haldun Guner. “Zinc and homocysteine levels in polycystic ovarian syndrome patients with insulin resistance.” Biological Trace Element Research 158, no. 3 (2014): 297–304.
49. Foroozanfard, F., M. Jamilian, Z. Jafari, A. Khassaf, A. Hosseini, H. Khorammian, and Z. Asemi. “Effects of zinc supplementation on markers of insulin resistance and lipid profiles in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial.” Experimental and Clinical Endocrinology and Diabetes 123, no. 04 (2015): 215–220; Ostadrahimi, Alireza. “Effect of zinc supplementation on cardiometabolic risk factors in women with polycystic ovary syndrome.” Journal of Cardiovascular and Thoracic Research 2, no. 2 (2010): 11–20.
50. Jamilian, Mehri, Fatemeh Foroozanfard, Fereshteh Bahmani, Rezvan Talaee, Mahshid Monavari, and Zatollah Asemi. “Effects of zinc supplementation on endocrine outcomes in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial.” Biological Trace Element Research 170, no. 2 (2016): 271–278.
51. Wall, Rebecca, R. Paul Ross, Gerald F. Fitzgerald, and Catherine Stanton. “Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids.” Nutrition Reviews 68, no. 5 (2010): 280–289.
52. McEwen, Bradley J. “Can omega-3 polyunsaturated fatty acids improve metabolic profile in polycystic ovary syndrome (PCOS)?” Advances in Integrative Medicine 4, no. 2 (2017): 82–83; Khani, Behnaz, Farahnaz Mardanian, and Sajadeh Jafari Fesharaki. “Omega-3 supplementation effects on polycystic ovary syndrome symptoms and metabolic syndrome.” Journal of Research in Medical Sciences 22 (2017); Forouhi, Neda, Sakineh Shab-Bidar, and Kurosh Djafarian. “Effect of omega-3 fatty acids supplementation on testosterone levels in women with polycystic ovary syndrome: Meta-analysis of randomized controlled trials.” Journal of Nutritional Sciences and Dietetics 1, no. 3 (2015): 165–170.
53. Ghent, W.R., B.A. Eskin, D.A. Low, and L.P. Hill. Iodine replacement in fibrocystic disease of the breast. Canadian Journal of Surgery 36, no. 5 (1993): 453–460; Naehrlich, Lutz, Helmuth-Günther Dörr, Azadeh Bagheri-Behrouzi, and Manfred Rauh. “Iodine deficiency and subclinical hypothyroidism are common in cystic fibrosis patients.” Journal of Trace Elements in Medicine and Biology 27, no. 2 (2013): 122–125.
54. Gerli, S., M. Mignosa, and G.C. Di Renzo. “Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial.” European Review for Medical and Pharmacological Sciences 7 (2003): 151–160; Iuorno, MD, Maria J., Daniela J. Jakubowicz, MD, Jean-Patrice Baillargeon, MD, Pamela Dillon, BS, Ronald D. Gunn, MS, Geoffrey Allan, PhD, and John E. Nestler, MD. “Effects of D-chiro-inositol in lean women with the polycystic ovary syndrome.” Endocrine Practice 8, no. 6 (2002): 417–423.
55. Raffone, Emanuela, Pietro Rizzo, and Vincenzo Benedetto. “Insulin sensitiser agents alone and in co-treatment with r– FSH for ovulation induction in PCOS women.” Gynecological Endocrinology 26, no. 4 (2010): 275–280.
56. Dinicola, Simona, Tony T.Y. Chiu, Vittorio Unfer, Gianfranco Carlomagno, and Mariano Bizzarri. “The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome.” The Journal of Clinical Pharmacology 54, no. 10 (2014): 1079–1092; Unfer, Vittorio, and Giuseppina Porcaro. “Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome.” Expert Review of Clinical Pharmacology 7, no. 5 (2014): 623–631; Monastra, Giovanni, Vittorio Unfer, Abdel Halim Harrath, and Mariano Bizzarri. “Combining treatment with myo-inositol and D-chiro-inositol (40: 1) is effective in restoring ovary function and metabolic balance in PCOS patients.” Gynecological Endocrinology 33, no. 1 (2017): 1–9.
57. Millea, Paul J. “N-acetylcysteine: multiple clinical applications.” American Family Physician 80, no. 3 (2009): 265–269.
58. Salehpour, Saghar, Azadeh Akbari Sene, Nasrin Saharkhiz, Mohammad Reza Sohrabi, and Fatemeh Moghimian. “N– acetylcysteine as an adjuvant to clomiphene citrate for successful induction of ovulation in infertile patients with polycystic ovary syndrome.” Journal of Obstetrics and Gynaecology Research 38,
